Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma

Loss of heterozygosity (LOH) at chromosomal loci has been associated with the presence of tumor suppressor genes at the deleted loci. Twenty‐six clinically localized, Stage B prostate carcinomas were analyzed for LOH on chromosomes 10 and 17 using microsatellite markers. Two of 26 carcinomas showed LOH on 17p while one showed LOH on 17q. Chromosome 10 showed a complex pattern of LOH with monosomy (1 case), LOH on 10p (1 case), proximal 10q (1 case) and distal 10q (2 cases). Overall 29% of informative cases showed LOH on chromosome 10. These results are consistent with the presence of a tumor suppressor for prostate cancer on 17p and multiple tumor suppressor genes on chromosome 10. © 1996 Wiley‐Liss, Inc.

[1]  M. Ittmann,et al.  Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. , 1994, The American journal of pathology.

[2]  S. Brewster,et al.  Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma. , 1994, The Journal of urology.

[3]  D. Morton,et al.  Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. , 1994, British journal of urology.

[4]  D. Louis,et al.  Molecular Genetics of Pediatric Brain Stem Gliomas. Application of PCR Techniques to Small and Archival Brain Tumor Specimens , 1993, Journal of neuropathology and experimental neurology.

[5]  P. Walsh,et al.  Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. , 1993, Cancer research.

[6]  P. Devilee,et al.  PCR-based microsatellite polymorphisms in the detection of loss of heterozygosity in fresh and archival tumour tissue. , 1993, British Journal of Cancer.

[7]  S. Hilsenbeck,et al.  p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.

[8]  F. Collins,et al.  A compound nucleotide repeat in the neurofibromatosis (NF1) gene. , 1993, Human molecular genetics.

[9]  D. Grignon,et al.  Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. , 1993, Cancer research.

[10]  W. Cavenee,et al.  Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. , 1993, Cancer research.

[11]  B. Seizinger.  NF1: a prevalent cause of tumorigenesis in human cancers? , 1993, Nature Genetics.

[12]  B. Darras,et al.  Loss of heterozygosity for alleles on chromosome 10 in human brain tumours. , 1993, Neurological research.

[13]  G. Olafsdóttir,et al.  Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. , 1992 .

[14]  D. Louis,et al.  A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens. , 1992, The American journal of pathology.

[15]  S. Daiger,et al.  Human chromosome 8 linkage map based on short tandem repeat polymorphisms: effect of genotyping errors. , 1992, Genomics.

[16]  Y. Nakamura,et al.  Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism , 1992, Genes, chromosomes & cancer.

[17]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.

[18]  J. Barrett,et al.  Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. , 1992, Cancer research.

[19]  E. Newcomb,et al.  p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. , 1992, Cancer research.

[20]  R. Cawthon,et al.  p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. , 1992, Cancer research.

[21]  D. Neal,et al.  p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. , 1992, The Journal of urology.

[22]  R. Chaganti,et al.  B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50 , 1991, Cell.

[23]  V. P. Collins,et al.  Allelotyping of human prostatic adenocarcinoma. , 1991, Genomics.

[24]  Y. Nakamura,et al.  Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma. , 1991, Cancer research.

[25]  U. Bergerheim,et al.  Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma , 1991, Genes, chromosomes & cancer.

[26]  T. Ishikawa,et al.  Allelotype study of primary hepatocellular carcinoma. , 1991, Cancer research.

[27]  U. Bergerheim,et al.  Recessive genetic mechanisms in the oncogenesis of prostatic carcinoma. , 1991, Scandinavian journal of urology and nephrology. Supplementum.

[28]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[29]  W. Isaacs,et al.  Allelic loss of chromosomes 16q and 10q in human prostate cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Thompson.  Growth factors and oncogenes in prostate cancer. , 1990, Cancer cells.

[31]  R. White,et al.  Allelotype of human malignant astrocytoma. , 1990, Cancer research.

[32]  J. Weber,et al.  Dinucleotide repeat polymorphism at the D15S87 locus. , 1990, Nucleic acids research.

[33]  G. Martin,et al.  Four classes of mRNA are expressed from the mouse int‐2 gene, a member of the FGF gene family. , 1988, The EMBO journal.